Pöördumine

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.29.2024 The World Health Organization (WHO) presents its compliments to Member States and Associate Members and would like to inform that all recommendations made by the 46th WHO Expert Committee on Drug Dependence (ECDD), held in October 2023, were accepted by the 67th UN Commission on Narcotic Drugs. WHO further has the pleasure of announcing that the 47th Expert Committee on Drug Dependence (ECDD) will meet from 14 to 18 October 2024 in Geneva, Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this circular letter serves to notify ... Member States of the agenda of the 47th ECDD, which are in the Annex I file, attached for reference. WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make recommendations to the UN Secretary-General on the need for and level of international control of psychoactive substances. To fulfil this mandate, WHO convenes the ECDD to advise on appropriate international drug control measures in view of a substance’s ability to lead to public health harms as a result of their psychoactive properties, as well as its therapeutic applications. Although the meetings are of a closed nature, Member States, Associate Members, individuals, and representatives of public and private institutions and civil society who wish to present information to the Expert Committee on issues related to the meeting agenda are invited to attend a virtual information meeting (public consultation) on 14 October 2024. The purpose of the information meeting is to afford the Expert Committee the opportunity to receive presentations and to question representatives of interested parties concerning data that have been provided about substances on the ECDD agenda. Registration information will be made available on the ECDD website in due course: Forty-seventh Expert Committee on Drug Dependence (who.int). As in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6), 1 Member States and Associate Members can also contribute to the ECDD review process by providing up to date and accurate information concerning the substances under review in advance of the meeting. For this purpose, and as per previous practice, a questionnaire will be sent to Member States and Associate Members to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation. 1 http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=90. ... ENCLS.: (2)  Page 2 C.L.29.2024 ... Annex II to this Circular Letter contains a list of national focal points officially designated by Member States and Associate Members in previous years who provide country information to the ECDD through the Member State Questionnaire referred to above. If the focal point information requires changes or amendments, Member States and Associate Members are invited to inform the WHO ECDD Secretariat by email to [email protected] by 15 July 2024 with the subject “47ECDD Focal Point: (Country Name)”. If the individual on the list is still the official focal point for completing the ECDD Member State Questionnaire this year and if no additions or amendments to focal point details are made by 15 July 2024, the focal point from the list will be given further instructions and direct access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be prepared as a report as part of the 47th ECDD substance review process. In addition to the questionnaire, Member States and Associate Members are also encouraged to provide any additional relevant information (unpublished or published) on the agenda by the 47th ECDD by emailing [email protected] with the subject “Ref: C.L.29.2024”. Finally, all technical reports and recommendations made by the ECDD are available online through the recently launched ECDD Information Repository (https://ecddrepository.org/en). The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration. GENEVA, 3 July 2024 47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE 14–18 October 2024 Provisional Agenda ---- Information Session (Public Consultation) 14 October 2024 Virtual 10:00–12:00 CEST 1. Welcome and opening of the meeting 2. Role and Mandate of the WHO Expert Committee on Drug Dependence (ECDD) 3. WHO ECDD review procedure and processes 4. Presentations and statements from participants 47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE 14–18 October 2024 Provisional Agenda 47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE 14–18 October 2024 Closed Session Geneva, Switzerland 1. Procedural matters and updates (a) Opening of the meeting and welcoming remarks (b) Procedural matters (i) Confidentiality of undertaking (ii) Declarations of Interest (iii) Election of Chair, Co-Chair, and Rapporteur (iv) Adoption of the agenda 2. Updates on priorities from international agencies (a) Briefings from international agencies on their work on the public health dimension of the world drug problem (b) Updates on WHO ECDD meetings and recommendations (i) Recommendations and outcomes of 46th ECDD (ii) Recommendations from working group on substance surveillance 3. Informal update: ECDD review of coca leaf 1 1 There has been a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a substance (Guidance on WHO review of psychoactive substances for international control, para 19(1)). In June 2023, WHO received an official notification from a Member State to conduct a critical review of coca leaf. Accordingly, in accordance with the Guidance on the WHO review of psychoactive substances for international control, a critical review of coca leaf is planned to be conducted in 2025 for the consideration of the Expert Committee on Drug Dependence. An informal update on preparations for such critical review will be presented at this meeting. 47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE 14–18 October 2024 4. Critical reviews: Recommendations on the scope of international control 2 (a) Synthetic cannabinoids (i) hexahydrocannabinol (HHC) (b) Novel synthetic opioids (i) N-pyrrolidino protonitazene (protonitazepyne) (ii) N-pyrrolidino metonitazene (metonitazepyne) (iii) Etonitazepipne (N-Piperidinyl etonitazene) (iv) N-Desethyl-Isotonitazene (c) Dissociative-type substance (i) 3-OH-PCP (3-Hydroxy-phencyclidine) (d) Cathinone/stimulant (i) N-ethylheptedrone (Ephylon) (e) Medicine 3 (i) Carisoprodol 5. Finalization of meeting report = = = 2 Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially serious risk to public health and society, and of no recognised therapeutic use by any Party (Guidance on WHO review of psychoactive substances for international control, para 19(4)). 3 The pre-review of a substance has resulted in an Expert Committee recommendation for critical review (Guidance on WHO review of psychoactive substances for international control, para 19(3)). Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Afghanistan Regulation Sector of Pharmaceutical Market and Albania Linda Ternova Specialist Medical Devices [email protected] Ministry of Health and Social Protection, Albania Narcotics, Psychotropics and Chemical Precursors, General Algeria Ghrieb Houria Doctor Direction of Pharmacy and Health [email protected] Equipment, Algerian Health Ministry Department of Health Resources Andorra Carla Lobaco Valls Technical Officer [email protected] and Medicines Department of Health Resources Andorra Carme Pallarés Papaseit [email protected] and Medicines Angola Antigua and Barbuda Director of Surveillance of Substances Subject to Special Argentina G. Rebaldería Pharmacist [email protected] Control Argentinian Ministry of Health Armenia Hasmik Martirosyan Armenian Ministry of Health [email protected] Research and International Policy Section Alcohol & Other Drugs Branch, Australia Population Health Division [email protected] 30 April 2024 Australian Government Department of Health and Aged Care Australia [email protected] Section VI, Department 6 Federal Ministry of Social Affairs, Austria Raphael Bayer Head of Division [email protected] Health, Care and Consumer Protection Azerbaijan Telman Suleyman Oglu Mammadhassanov [email protected] Bahamas Bahrain Samar Yousef Salem Senior Pharmacist Ministry of Health [email protected] Health Services Division, Bangladesh Habibur Rahman Khan Additional Secretary Ministry of Health & Family [email protected] Welfare Barbados Lindsay Bynoe Assistant Director for Drug Regulation Ministry of Health [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Belarus Aleksey Kralko Ministry of Health [email protected] Epidemiology and Public Health, Head of Unit illicit Drugs, Reitox National Belgium Lies Gremeaux Sciensano, [email protected] Focal Point Ministry of Health Belize State-certified Pharmacist, Head of Pharmaceutical Establishments Benin Saturnin Bognon Pharmaceutical Establishments [email protected] Department Department Department of Public Health, Bhutan Dil Kumar Subba [email protected] Ministry of Health Bolivia (Plurinational State of) Maria Julia Carrasco [email protected] [email protected]; Bosnia and Herzegovina [email protected] Department for Health, Ministr of Bosnia and Herzegovina Sabina Šahman the Civill Affairs of Bosnia and [email protected] Herzegovina Department of Clinical Services, Botswana Vivian Sebako Chief Pharmacist [email protected] Ministry of Health and Wellness Management of Controlled Products GPCON/GGMON/DIMON/ANVISA Brazil Renata de Morais Souza, Moema Luisa Silva Macedo Manager [email protected] Controlled Substances Office Brazilian Health Regulatory Agency – ANVISA International Affairs Office, Brazil Natalia Jorge e Costa Brazilian Health Regulatory Agency [email protected] - ANVISA, AINTE/ GADIP/ANVISA Acting Director of Pharmaceutical Department of Pharmaceutical Brunei Darussalam Hajah Zanatul ‘Aini Haji Zainin (Ms) [email protected] Services Services, Ministry of Health Department Health Promotion and Bulgaria Slaveyka Nikolova Chief Expert at the Health Promotion Prophylaxis of the Diseases and [email protected] Addictions Directorate Mental Health and Addiction Head of the National Focus Center Prevention Directorate, National Bulgaria Alexander Panayotov [email protected] Department Center for Public Health and Analysis Burkina Faso [email protected] Burundi Israël Nimubona [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Commission for the Coordination of Alcohol and Other Drugs, Cabo Verde Zania Correia e Silva [email protected] Ministerio da Saude e da Seguranca Social Department of Mental and Cambodia Chhit Sophal Director Substance Abuse, Ministry of [email protected] Health Cameroon Ketchozo Loko Wilfried [email protected] International Relations Unit, Office of Drug Policy and Science, Canada Controlled Substances Directorate, [email protected] 4/26/2024 Health Canada, Government of Canada Central African Republic Deputy Director of Pharmacy and Chad Haoua Haroun Saker Ministry of Public Health [email protected] Medicine Department of Mental Chile Javiera Erazo Leiva Advisor [email protected] Health/DIPRECE, Ministry of Health China Zhendong HUA Deputy Director National Narcotics Laboratory [email protected] Office of National Narcotics China Yan ZHENG Official [email protected] Control Commission China Peng XU Senior Expert National Narcotics Laboratory [email protected] Observatorio de Drogas de Colombia Colombia Oscar Ricardo Santana Dirección de Políticas de Drogas y [email protected] Actividades Relacionadas Ministerio de Justicia y del Derecho Colombia [email protected] Coordinator of the Social Coexistence and Citizenship Group Colombia A. Peñuela Advisor to the Minister's Office [email protected] of the Directorate of Promotion and Prevention Comoros Cook Islands Tereapii Uka Central Policy and Planning Office [email protected] Costa Rica Marchena Vasquez [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Côte d'Ivoire Ernest Zotoua [email protected] Administration for Primary Health Care, Health Tourism, Medicines and Medical Products, Public Croatia Romana Katalinić Head of Sector [email protected]    Health and Public Health Protection Ministry of Health Cuba Pharmaceutical Services, Ministry Cyprus John Kkolos Pharmacist [email protected] of Health Inspectorate Department, Narcotic Czechia Vlastimil Brandejs and Psychotropic Substances [email protected] Ministry of Health Democratic People's Republic of Kim Jong Guk Korea Democratic Republic of the Congo Ghislaine Mbelu Kanyunya [email protected] Head of Focal Point, Prevention, Denmark Kari Gragaasen Chief Consultant [email protected] National Board of Health Djibouti Ministry of Health, Wellness and Dominica Laura Esprit Chief Medical Office [email protected] New Health Investment Ministry of Health, Wellness and Dominica Anna Royer-Edmund Chief Pharmacist [email protected] New Health Investment Dominican Republic [email protected] General Directorate of Medicines, Head of the Assistive Technology Food and Health Products Dominican Republic Francisca Dalia Castillo Sanchez [email protected] Department (DIGEMAPS), Ministry of Public Health International Drug Commissioner and Head of the Management functions of the Project for the Creation and Ecuador María Ignacia Páez Monge [email protected] Implementation of Services of the Community Mental Health Network and State Addiction Recovery Centers Project for the Creation and Implementation of Services of the Ecuador Ileana Isabel Espinosa Soto [email protected] Community Mental Health Network and State Addiction Recovery Centers, Egypt [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Focal Point of the Ministry of Health of El Health Technology Department, El Salvador José Mauricio Bermúdez Recinos [email protected] Salvador Ministry of Health Equatorial Guinea Eritrea Michael Girmay Haile [email protected] State Agency of Medicines, Estonia Olga Kamp Specialist in the Inspection Bureau [email protected] Ministry of Health Eswatini Ethiopia Baharu Zewdie Moya [email protected] Faroe Islands Pharmaceutical & Biomedical Fiji Ilisabeta May Pesamino Chief Pharmacist Services/Ministry of Health & [email protected] Medical Services Finnish Medicines Agency, Finland Katja Pihlainen [email protected] Ministry of Health Regulation of narcotics and psychotropic substances, France Luciano Amato Acting Head of Department [email protected] National Agency for the Safety of Medicines and Health Products Directorate of Medicines and Gabon Okouyi Ndakissa Pharmacy [email protected] Ministry of Health Gambia Division of Legal Circulation of Narcotic Drugs, LEPL State Regulation Agency for Medical Georgia Ekaterine Paposhvili Senior Specialist [email protected] Activities Ministry of Labour, Health and Social Affairs of Georgia Division 122 - Narcotics Law, Traffic in Narcotics, International Germany Annette Hinze [email protected] Narcotic Drug Affairs Federal Ministry of Health Pharmaceutical Services, Ministry Ghana Martha Gyansa-Lutterodt Director [email protected] of Health University Mental Health Research Greece Ioanna Siamou Responsible for the Early Warning System [email protected] Institute Greece Maria Kouloumpi Head of the Directorate of Dependencies Hellenic Ministry of Health [email protected];[email protected] Grenada Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Guatemala Karem Ermely Sagastume Aguirre [email protected] Guatemala Shuandy Alejandra Milian Recinos [email protected] Guatemala Beatriz Eugenia Batres Rivera [email protected] Guinea Guinea-Bissau Guyana Haiti Marie Judith Robuste Roche Ministry of Health [email protected] Honduran Institute for the General Director of the Honduran Prevention of Alcoholism, Drug Honduras Alex Virgilio Santos Moreno [email protected] Institute for the Prevention of Alcoholism Addiction and Drug Dependence (IHADFA) EMMI Pharmaceutical and Medical Hungary Tímea Kahlesz Deputy Head of Department [email protected] Technology Department Iceland Bjarni Sigurðsson Ministry of Health [email protected] Department of Psychiatry, National Drug Dependence India Rakesh Chadda Professor and Head [email protected] Treatment Centre, All India Institute of Medical Sciences Directorate General of Director of Pharmaceutical Production Indonesia Agusdini Banun Saptaningsih Pharmaceutical Care and Medical [email protected] and Distribution Devices, Iran (Islamic Republic of) Mina Azhoogh [email protected] Iraq Emad Abdulrazzaq Abdulghani Ministry of Health [email protected] Ireland Conor Brennan Department of Health [email protected] Ireland Alan Bell Department of Health [email protected] Israel Paola Rosca Head of the Addiction Treatment Departm Ministry of Health [email protected] The Competent Authority for Narcotics, Psychotropics and Israel Tal Lavy [email protected] Precursors Pharmaceutical Administration Ministry of Health - Directorate Italy Pietro Canuzzi Medical Doctor [email protected] general of Health Prevention Central Narcotics Office, Ministry Itay Rocco Signorile [email protected] of Health Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Jamaica Dr Jacquiline Bisasor McKenzie Chief Medical Officer Ministry of Health & Wellness [email protected] National Council on Drug Abuse Jamaica Michael Tucker Executive Director [email protected] (NCDA) National Council on Drug Abuse Jamaica Uki Atkinson Research Analyst [email protected] (NCDA) Compliance and Narcotics Division, Japan [email protected] Pharmaceutical Safety and Environmental Health Bureau Head of Narcotics, Psychotropic Substances and Chemical Jordan Malak AlMahirah Precursors Department, [email protected] Jordan Food and Drug Administration Republican Scientific and Practical Kazakhstan Prilutskaya Marina [email protected] Center of Mental Health Kenya Anthony Toroitich [email protected] Kenya Simon Njuguna [email protected] Ministry of Health and Medical Kiribati Biribo Kararaiti Chief Pharmacist [email protected] Services Control of Licenses for Narcotic Kuwait Ali Abdulmohsen Jaragh Pharmacist Drugs and Psychotropic [email protected] Substances Department Drug Trafficking Control Kyrgyzstan Kanyshai Damirbek Department, [email protected] Ministry of Foreign Affairs Head of Health Promotion and Nutrition Department of Hygiene and Health Lao People's Democratic Republic Khatthanaphone Phandoangsy [email protected] Unit Promotion, Ministry of Health Latvia Linda Veisberga Ministry of Health [email protected] Lebanon Marie-Therese Matar Head of Narcotics Department Ministry of Public Health [email protected] Lesotho Masello Sello [email protected] National Controlled Substance Division of Pharmaceutical Liberia Dr David Zubah Sakui [email protected] Coordinator Sciences (DPS) Libya Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Drug Precursors Control and Risk Head of Drug Precursors Control and Risk Assessment Division, Lithuania Rima Mačiūnienė [email protected] Assessment Division Drug, Tobacco and Alcohol Control Department Luxembourg Alain Origer National Drug Coordinator Ministry of Health [email protected] Laboratories and Traditional Madagascar Maximine Ravaoarimanana Director of Pharmacy [email protected] Medicine Assistant Director of Clinical Services Malawi Michael Udedi [email protected] (Mental Health and Substance Abuse) Pharmaceutical Services Division, Malaysia Rohaida Binti Zakaria Senior Principal Assistant Director [email protected] Ministry of Health Medicine and Therapeutic Goods Deputy Director General, Maldives Aishath Mohamed Division, [email protected] Pharmaceuticals Maldives Food and Drug Authority Mali Mahamadou Ousmane Maiga [email protected] Office of the Superintendence of Malta Victor P. Pace Public Health, [email protected] Department for Health Regulation Marshall Islands Julia Alfred Ministry of Health [email protected] Mauritania Hamoud Fadel Yamohomed Director of Pharmacy and Laboratories Ministry of Health [email protected] Harm Reduction Unit, Ministry of Mauritius Nitish Raj Sokool Officer-in-Charge [email protected] Health and Wellness Mauritius Anil Jhugroo Advisor on Substance Abuse Ministry of Health and Wellness [email protected] COFEPRIS representative, Federal Mexico Angélica Juárez Ramírez Specialized Reviewer Committee for Protection from [email protected] Sanitary Risks Micronesia (Federated States of) Benido Victor [email protected] Pharmacy Inspector, Health Monaco Isabelle Kessedjian Head of Division [email protected] Products Division Mongolia Luvsandagva Purevdorj [email protected] Montenegro Jasna Sekulic Ministry of Health [email protected] Morocco Hassan Elkarimi [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Professor of Psychiatry, Rabat Faculty of Medicine, Director of the National Centre on Drug Morocco Jallal Toufiq Abuse Prevention, Treatment and [email protected] Research, Director of the Moroccan Observatory on Drugs and Drugs Addictions Mozambique Flavio Mandlate [email protected] Drug Dependency Treatment and Program Manager/ Consultant Myanmar Nanda Myo Aung Wan Research Unit, [email protected] Psychiatrist Ministry of Health and Sport Namibia Ester Mvula Senior Pharmacist Ministry of Health & Social Services [email protected] Nauru Richard Leona Chief Surgeon Ministry of Health [email protected] Nepal Nutrition, Health Protection and Prevention Department, Netherlands (Kingdom of the) Matthijs Geilenkirchen [email protected] 29 April 2024 Ministry of Health, Welfare and Sport Regulatory Practice and Analysis, New Zealand Tania Jones [email protected] Medsafe Nicaragua Karla Vanessa Delgado Martinez Director of Pharmacy Ministry of Health [email protected] Niger Haoua Na Allah Alou [email protected] Narcotics and Drug Abuse Programme, Pharmaceutical Head Narcotics and Drug Abuse Services Division, Nigeria Rafiu Akanbi Folarin [email protected] Programme Department of Food and Drug Services, Federal Ministry of Health Niue North Macedonia Narcotic Drugs Control, Norway Anne S. Onsgård Sagabråten [email protected] Norwegian Medicines Agency Oman Mahmood Al Abri [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Directorate General of Pharmaceutical Affairs and Drug Oman [email protected] control, Ministry of Health Pakistan Rizwan Taj Professor Ministry of Health [email protected] Division of Ancillary Services, Bureau of Hospital and Clinical Palau Clarette Matlab Chief Pharmacist [email protected] Services, Ministry of Health Palau [email protected] Palau Marla Ito [email protected] Head of the Mental Health Section of the General Directorate of Health of Panama Delia De Ycaza [email protected] General Directorate of Public Health the Ministry of Health Program Manager-Non Communicable Public Health Division, National Papua New Guinea Vicky Wari [email protected] Diseases Department of Health Paraguay Laura Patricia Perez Villaverde [email protected] Paraguay Zaira Francesca Stumpfs Bigarella [email protected] Head of Functional Unit of Controlled DIGEMID – General Directorate of Peru Judith Castañeda Alcántara [email protected] Products Medicines, Supplies and Drugs Philippines Information Centre for Drugs and Drug Addiction (CINN) Poland Michał Kidawa Polish Reitox Focal Point [email protected] National Bureau for Drug Prevention Intervention Service for Addictive Behaviours and Addictions Director of Planning and Intervention General Directorate for Portugal Graça Vilar [email protected] Services Directorate Intervention on Addictive Behaviours and Dependencies SICAD Puerto Rico Director of addiction and CL at Hamad Medical Corporation Qatar Majid Ali Al Abdulla Senior Consultant Psychiatrist Deputy Chairman of Mental Health [email protected] Services, Hamad Medical Corporation Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Narcotics Policy Division of Republic of Korea Hyun Jun Kim [email protected] Ministry of Food and Drug Safety Standing Committee on Drugs Control, Republic of Moldova Oleg Costachi [email protected] Agency for Medicines and Medical Devices Romania Camelia Bunaciu Senior Advisor Ministry of Health [email protected] Department for regulation of Russian Federation Alyona Ryzova Deputy Head of the Unit for regulatory andmedicines and medical devices, [email protected] Ministry of Health Rwanda Saint Kitts and Nevis puerto rico Substance Abuse Advisory Council Coordinator of the Substance Abuse Saint Lucia Charlotte Emmanuel Secretariat, [email protected] Advisory Council Secretariat Ministry of Health and Wellness Substance Abuse Advisory Council Saint Lucia Paul Caleb Programme Officer Secretariat, [email protected] Ministry of Health and Wellness Saint Vincent and the Grenadines Samoa Robert Thomsen Assistant Chief Executive Officer HSPQA, Medical and Allied Division [email protected] San Marino Claudio Muccioli Health Authority Director Health Authority [email protected] Sao Tome and Principe Administration of controlled preparations, Executive Management for Saudi Arabia Adnan Alshammary Regulatory Affairs, [email protected] Controlled Products Department, Regulatory Affairs Directorate, Drug Sector Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Pharmaceutical Regulatory Agency, Senegal Moussa DIALLO Pharmacist Inspector Ministry of Health and Social [email protected] Action Monitoring Centre for Drugs and Drug Addiction, Sector for Medicines and Medical Devices, Serbia Nataša Savić [email protected] Psychoactive Controlled Substances and Precursors, Ministry of Health Seychelles Sierra Leone Senior Executive (International Personal Assistant to Director Cooperation) Singapore Ong Lay Tin [email protected] (International Cooperation) Public Health Group, Ministry of Health National Monitoring Centre for Drugs, Department of Anti-Drug Strategy Slovakia Peter Koreň Reitox National Focal Point [email protected] 4/8/2024 Coordination and Drug Monitoring, Ministry of Health of the Slovak Republic Directorate of Public Health, Slovenia Joze Hren Secretary [email protected] Ministry of Health National Mental Health Service, Solomon Islands Paul Orotaloa Head of Mental Health Services Ministry of Health and Medical [email protected] Services National Mental Health Service, Solomon Islands Stephen Araitewa Director Mental Health Ministry of Health and Medical [email protected] Services Somalia South Africa MG Molewa Ministry of Health [email protected] Director General of Pharmaceuticals and South Sudan Moses Malual Deng Ministry of Health [email protected] Medical Supplies Head of Department Inspection & Spanish Agency of Medicines and Spain Manuel Ibarra [email protected] Enforcement Medical Products (AEMPS) Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Narcotics and Psychotropic Substances Area, Pharmaceutical Inspection and Spain Lidia Fernandez Matellano [email protected] Enforcement Department, Spanish Agency of Medicines and Medical Products (AEMPS) Sri Lanka S.C. Wickramasinghe Deputy Director General (NCD) Ministry of Health [email protected] Sudan Suriname Ministry of Health and Social Affairs, Sweden Ms Kajsa Mickelsson [email protected] 4/8/2024 Division for Public Health and Health Care Federal Department of Home Affairs, Federal Office of Public Switzerland Lucien Colliander [email protected] Health, Division of International Affairs, Global Health Section Swissmedic, Swiss Agency for Switzerland Monika Joos Head of Division Narcotics [email protected] Therapeutic Products Mental Health Directorate, Syrian Arab Republic Ahmed Al-Salama [email protected] Ministry of Health Tajikistan Salim Abdulazizov [email protected] Narcotics Control Division (Standards and Regulations Sub- Thailand Sujinart Chantharakul Pharmacist Division), [email protected] Food and Drug Administration, Ministry of Public Health Narcotics Control Division (Standards and Regulations Sub- Thailand Saranya Chavanich Pharmacist Division), [email protected] Food and Drug Administration, Ministry of Public Health Narcotics Control Division Thailand Korapin Na Ranong Expert on Narcotics Epidemiology Food and Drug Administration, [email protected] Ministry of Public Health Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Narcotics Control Division Thailand Raththar Benchapalanont Pharmacist Food and Drug Administration, Ministry of Public Health Pharmacovigilance and Medicine Control Department, National Timor-Leste Soares Henriques Regulatory Affairs Pharmacist [email protected] Directorate for Pharmaceutical and Medicines, Ministry of Health Togo Mouhoudine Yerima Centre National de Pharmacovig [email protected];[email protected] Tokelau Central Pharmacy and Medical Tonga Melenaite Mahe Principal Pharmacist Store, Old Vaiola, Ministry of [email protected] Health Trinidad and Tobago Anesa Doodnath-Siboo Principal Pharmacist Ministry of Health [email protected] Tunisia Pharmacovigilance and Medicine Head Turkish Medicines and Medical Control Department, National Türkiye Demet Aydınkarahaliloğlu [email protected] Devices Agency Directorate for Pharmaceutical and Medicines, Ministry of Health Turkmenistan Tuvalu Mental Health and Control of Head of Mental Health and Control of Uganda Hafsa Lukwata Substance Abuse Division, [email protected] Substance Abuse Ministry of Health Institute of Psychiatry, Forensic Ukraine Deputy Director Psychiatric Examination and Drug [email protected] Monitoring, Institute of Psychiatry of Taras Shevchenko National University of Kyiv, Ukraine Irina Pinchuk Director International Technology Transfer [email protected] Center - Ukraine Head of ISSUP Ukraine National Chapter Institute of Psychiatry, Taras Ukraine Yulia YACHNYK Clinical Psychologist Shevchenko National University of [email protected] Kyiv Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Product & Precursor Chemicals United Arab Emirates Alia Bin Hussain Head of Regulating Controlled substances Drug Department, [email protected] Ministry of Health and Prevention Addiction and Inclusion Directorate, United Kingdom of Great Britain and Project Manager Drugs Research and Office for Health Improvement & Alberto Oteo [email protected] Northern Ireland Surveillance Disparities, Department of Health and Social Care Pharmaceutical Service Unit, United Republic of Tanzania Suma Jairo Pharmacist [email protected] Ministry of Health Center for Drug Evaluation and Senior Pharmacologist and International United States of America Edward Hawkins research, [email protected] Drug Control Liaison U.S. Food and Drug Administration Mental Health Program Area, Uruguay Horacio Porciuncula [email protected] Ministry of Public Health Uzbekistan Lenakel Health Office, Vanuatu Jerry Iaruel Tafea Provincial Health Administrator [email protected] Ministry of Health Venezuela (Bolivarian Republic of) Viet Nam Mhin Tam Nguyen Regulatory Affair Consultant Ministry of Health [email protected] Yemen Zambia Nita Besa Head Clinical Care Chainama Hospital [email protected] Zimbabwe Eneti Siyame Mental Health Manager Ministry of Health and Child Care [email protected] Saatja: [email protected] Teema: WHO: C.L.29.2024 (47th ECDD) Kuupäev: 2024-07-03 14:56 Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.29.2024 regarding the 47th Expert Committee on Drug Dependence (ECDD) to be held from 14 to 18 October 2024. Should you have questions regarding C.L.29.2024 please send an email to [email protected]. Best regards, Department of Governing Bodies World Health Organization ***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***